Table 2

Baseline Demographics and Clinical Characteristics

BT (n = 45)

Control (n = 24)


Age (yrs)

40.0 ± 11.2

40.8 ± 12.1


Gender

Male 19 (42%)

Male 9 (38%)

Female 26 (58%)

Female 15 (63%)


Race

White 41 (91%)

White 22 (92%)

Black 3 (7%)

Black 2 (8%)

Asian 1 (2%)

Asian 0 (0%)


Height (cm)

166.1 ± 9.6

164.8 ± 7.7


Weight (kg)

76.3 ± 23.3

77.7 ± 16.9


Inhaled Corticosteroid Dose (μg)a

1305 ± 880

1141 ± 1053


LABA Dose (μg)b

109 ± 34

100 ± 15


Symptom-Free Days (%)

33.3 ± 34.3

46.1 ± 41.0


Asthma Control Questionnaire (ACQ) Score

1.3 ± 0.6

1.2 ± 0.7


Asthma Quality of Life Questionnaire (AQLQ) Score

5.6 ± 0.9

5.6 ± 0.9


Rescue Medication Use (No. of puffs/7days)

10.6 ± 14.7

5.5 ± 10.4


Emergency Room Visits for Respiratory Symptoms in prior 12 months c

No. Events (No. Subjects)

3 (3)

0 (0)


Hospitalizations for Respiratory Symptoms in prior 12 months c

No. Events (No. Subjects)

3 (3)

2 (2)


Lung Function Measures


Morning PEF (L/min)

368.4 ± 99.7

394.1 ± 111.7


Pre-Bronchodilator FEV1 (% predicted)

72.5 ± 10.9

74.9 ± 8.9


Post-Bronchodilator FEV1 (% predicted)

84.4 ± 13.8

86.1 ± 9.5


Diffusion Capacity (mL/min/mm Hg)

15.7 ± 10.7

15.9 ± 11.7


Total Lung Capacity (L)

6.0 ± 1.2

5.9 ± 1.3


Residual Volume (L)

2.1 ± 0.7

2.0 ± 0.7


Methacholine PC20 (mg/ml)

0.25

0.28

Geometric mean (range)

(0.2, 0.4)

(0.1, 0.6)


Definition of abbreviations: BT = Bronchial Thermoplasty; LABA = Long-Acting β2-Agonist;

PEF = Peak Expiratory Flow Rate; FEV1 = Forced Expiratory Volume in 1 second.

Values are mean ± SD.

a: Beclomethasone or equivalent.

b: Salmeterol or equivalent.

c: Patient reported.

BT versus Control: All parameters, Not significant (Student's t-test of the mean).

Thomson et al. BMC Pulmonary Medicine 2011 11:8   doi:10.1186/1471-2466-11-8

Open Data